Results

1–5 of 5 results for Eric W Schneider

Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Baseline Characteristics Associated With Catastrophic Vision Loss Due to Subretinal Hemorrhage in Patients Undergoing Treatment for Neovascular Macular Degeneration
Eric W Schneider, MD
Annual Meeting Talks
2024
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Updates from the Field
2025
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Updates from the Field
2019
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Annual Meeting Talks
2019